We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multiplex Genotyping Developed for Rare Blood Types

By LabMedica International staff writers
Posted on 21 Mar 2013
A multiplex polymerase chain reaction combined with DNA pooling for mass screening has been developed for rare blood types.

All existing sequence-specific primers polymerase chain reaction (PCR-SSP) assays for blood typing, genotype one or several single-nucleotide polymorphisms (SNPs) individually, but DNA pooling is a way that reduces the amount of genotyping required.

Scientists at the Shanghai Blood Center (China) established a sensitive multiplex PCR-SSP assay testing pooled DNA to detect the rare Fyb and S alleles. It was applied to screen a total of 4,490 donor samples via testing of 898 DNA pools. The samples in the positive pools were further tested individually. Genomic DNA was extracted from ethylenediaminetetraacetate (EDTA) anticoagulated blood samples using the TIANamp Genomic DNA Kit (Tiangen Biotech; Beijing, China). Every five DNA samples of the 4,490 donors screened were pooled before the multiplex PCR.

Two hundred and fifty-four donors were tested positive for the Duffy Fyb allele, whereas 101 donors were positive for the S allele. Among the 254 Fy(b+) donors, five were Fy(a−b+) and 249 were Fy(a+b+). Among the 101 S+ donors, three were S+s− and 98 were S+s+. The rare Fyb and S alleles comprised 2.28% and 1.16%, respectively. The PCR-SSP assays were confirmed by sequencing analysis and serological testing.

The authors concluded that this genetic high-throughput screening provides a means of detecting relatively large numbers of donors while providing, to a certain extent, antigen-negative blood for “difficult” patients with rare antibodies. The multiplex PCR assay was combined with DNA pooling to reduce the number of tests required, making large-scale screening feasible, and a cost-effective strategy. The study was published on January 22, 2013, in the journal Transfusion Medicine.

Related Links:
Shanghai Blood Center
Tiangen Biotech


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Centromere B Assay
Centromere B Test

Latest Hematology News

New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder

Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy

WBC Count Could Predict Severity of COVID-19 Symptoms



Sekisui Diagnostics UK Ltd.